Clinical Trial Update: L-Glutamine Therapy for Sickle Cell Anemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of L-Glutamine therapy for sickle cell anemia has been terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Thalassemia

Drugs mentioned

• L-GLUTAMINE (L-Glutamine)

Snippet

Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Conditions: Sickle Cell Anemia, Thalassemia | Phase 2 | Status: TERMINATED | Results posted: 2021-02-02